HIV Treatment · Drug Access · Global Pricing
Biktarvy Price in India: The Definitive 2026 Guide to Costs, Licensed Generics, and Safe Personal Import Options
Brand-name Biktarvy costs $4,216 per month in the United States. The identical drug — produced under Gilead’s own voluntary license — costs $95–$165 per month in India. This guide explains precisely why that price gap exists, which Indian generics are legitimate and safe, what the FDA’s personal importation policy actually permits, and which U.S. assistance programs to exhaust first. Every claim is sourced and linked.
This article is for informational purposes only. It does not constitute medical, legal, or financial advice. Always consult a licensed HIV physician before changing your treatment source. If you are in the United States and considering personal importation, consult a healthcare attorney familiar with FDA import regulations.
What Is Biktarvy? Active Ingredients & Approvals
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, also written BIC/FTC/TAF) is a once-daily, single-tablet antiretroviral therapy (ART) developed by Gilead Sciences. It treats HIV-1 infection in adults and pediatric patients who are treatment-naive or virologically suppressed and wish to switch regimens.
The fixed-dose combination contains three active pharmaceutical ingredients:
- Bictegravir (BIC) 50 mg — second-generation integrase strand transfer inhibitor (INSTI) with a high genetic barrier to resistance
- Emtricitabine (FTC) 200 mg — nucleoside reverse transcriptase inhibitor (NRTI)
- Tenofovir alafenamide (TAF) 25 mg — prodrug nucleotide reverse transcriptase inhibitor with improved renal and bone safety vs. older TDF
Biktarvy received U.S. FDA approval on February 7, 2018. The European Medicines Agency approved it in June 2018; Health Canada and Australia’s TGA in July 2018. India’s Drug Controller General (DCGI) approved a licensed generic version in 2019. As of 2025, Biktarvy is recommended as a preferred first-line regimen in U.S. DHHS Antiretroviral Guidelines.
Biktarvy Price in India vs. USA — The Numbers
The price gap between Biktarvy in India and the United States is one of the most extreme examples of pharmaceutical price disparity in global medicine. Here are the verified figures.
Biktarvy U.S. List Price — Sources
According to Gilead Sciences’ own public pricing transparency website, the Wholesale Acquisition Cost (WAC) of Biktarvy as of January 1, 2026 is $4,216.00 per 30-tablet bottle. In January 2025, Biktarvy’s WAC increased by 5.9% — one of 590 pharmaceutical price changes at the start of the year, with only 7 drugs seeing reductions.
📌 Gilead Price Info — Official Biktarvy Pricing
📌 Drugs.com — Biktarvy Price Guide
📌 GoodRx — Biktarvy Without Insurance
Biktarvy Price in India — Sources
Verified international pharmacy comparison platforms confirm Indian generic Biktarvy equivalents (BIC/FTC/TAF 50/200/25 mg) are available in the $60–$150 per month range, depending on the generic brand and verified pharmacy channel.
Why Is Biktarvy 98% Cheaper in India?
Five structural factors explain why Biktarvy costs 95–98% less in India. These are not loopholes or accidents — they are the result of deliberate legal, policy, and market decisions by governments, international health organizations, and Gilead Sciences itself.
1. India’s Section 3(d) Patent Law Prevents “Evergreening”
India’s Patents Act (1970, amended 2005) contains a landmark provision — Section 3(d) — that prevents pharmaceutical companies from obtaining new patents by making minor modifications to existing molecules. This blocks “evergreening,” the practice of extending patent monopolies through trivial reformulations. As a result, many drugs still patent-protected in the U.S. can be legally manufactured as generics in India once a voluntary license is in place.
India’s Section 3(d) does not make all drugs generic — it prevents trivial patent extensions. Generic Biktarvy production in India requires Gilead’s Voluntary License, which was formally granted in 2017. It is fully legal and licensed.
2. Gilead’s Voluntary License with the Medicines Patent Pool
In 2017, Gilead Sciences entered into a Voluntary Licensing Agreement with the Medicines Patent Pool (MPP), covering bictegravir — the key patented INSTI component of Biktarvy. This authorized 20+ Indian manufacturers to produce generic bictegravir combinations for distribution across 116 low- and middle-income countries. Gilead receives only a modest royalty on these sales.
📌 Gilead Press Release — MPP Voluntary License for Bictegravir (2017)
📌 Medicines Patent Pool — Official Website & License Database
3. India Is the World’s Largest Antiretroviral Producer
Hetero Drugs, headquartered in Hyderabad, is the world’s largest manufacturer of antiretroviral medicines by volume. India’s pharmaceutical industry supplies ARVs to over 150 countries. This scale creates a hyper-competitive generic market where manufacturing quality is high and prices are driven down by competition among dozens of licensed producers.
4. Lower Manufacturing Costs + Mature API Infrastructure
India has built one of the world’s most advanced Active Pharmaceutical Ingredient (API) manufacturing ecosystems over five decades. Labor, energy, and regulatory compliance costs are structured for high-volume generic production. This is efficient, quality manufacturing — not cheap manufacturing.
5. The U.S. Lacks Centralized Drug Price Negotiation
In the UK, Germany, France, Canada, and Australia, governments negotiate drug prices with manufacturers as a condition of market access. The U.S. did not have this mechanism for most drugs until the Inflation Reduction Act (2022) introduced limited Medicare negotiations. Additionally, the U.S. allows pharmaceutical direct-to-consumer advertising (banned in most countries) and has a complex pharmacy benefit manager (PBM) system that adds cost rather than reducing it.
6. Indian Government Price Controls & Free National ART Program
India’s National AIDS Control Programme (NACP) provides free antiretroviral therapy through a national network of ART centers. The National Pharmaceutical Pricing Authority (NPPA) also has authority to cap prices on essential medicines, which creates structural downward pressure on ARV prices market-wide.
Biktarvy Price by Country — Global Comparison
| Country | Approx. Monthly Price | Brand / Status | Why This Price |
|---|---|---|---|
| 🇺🇸 United States | $4,216 (list) | Brand only (Gilead) | No generic; no national price negotiation for most of market |
| 🇮🇳 India | $60–$150 | Licensed generics (TAFFIC, others) | Voluntary license; 20+ manufacturers; Section 3(d) patent law |
| 🇲🇽 Mexico | ~$400–$600 | India-sourced generics + markup | Imported from India with distribution margin |
| 🇬🇧 United Kingdom | Heavily subsidized | Brand (NHS negotiated) | NHS negotiates; covered free for patients |
| 🇩🇪 / 🇫🇷 Germany / France | Significantly subsidized | Brand (national formulary) | Mandatory price negotiation (AMNOG in Germany) |
| 🇨🇦 Canada | Lower than U.S.; varies | Brand (PMPRB regulated) | Patented Medicine Prices Review Board caps prices |
| 🇦🇺 Australia | ~A$6–$42 per month | Brand (PBS listed) | Pharmaceutical Benefits Scheme covers Biktarvy |
The Biktarvy available in Mexico is largely exported from licensed Indian manufacturers. Even after shipping, distribution margins, import duties, and local pharmacy markup, the price remains a fraction of U.S. costs — illustrating just how extreme U.S. pharmaceutical pricing is in global context.
Gilead’s Voluntary License: The Legal Foundation of Indian Generics
Indian generic Biktarvy is not counterfeit. It is produced under a formal, fully documented voluntary license granted by Gilead Sciences. Below is the complete, verified chain of legal authority.
Gilead Sciences holds the original patent on bictegravir and the Biktarvy combinationThe patent covers bictegravir (BIC) and its combination with FTC and TAF. U.S. patent protection extends through the mid-2030s.
In 2017, Gilead licensed bictegravir to the Medicines Patent Pool (MPP)Gilead granted the MPP the right to sub-license bictegravir production to generic manufacturers in developing countries. This was the first major INSTI voluntary license for a next-generation HIV drug.
The MPP sub-licensed 20+ Indian manufacturers covering 116 countriesLicensed companies include Hetero Drugs, Cipla, Sun Pharma, Mylan (Viatris), Strides Pharma, SeQuent Scientific, and others. Each signed a sub-license agreement with quality and distribution requirements.
India’s DCGI approved the generic version in 2019The Drug Controller General of India reviewed and approved the generic BIC/FTC/TAF 50/200/25 mg combination, meeting Indian regulatory standards.
Hetero Drugs launched TAFFIC in December 2019 — the first Indian generic Biktarvy equivalentManufactured at Hetero’s Hyderabad facility, TAFFIC is produced in a plant approved by multiple international regulatory bodies. Hetero is the world’s largest ARV manufacturer by volume.
Licensed Generic Biktarvy Brands Available in India
All products listed below contain the same active ingredients as brand-name Biktarvy: Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir Alafenamide 25 mg in the same once-daily oral tablet formulation, all produced under the MPP voluntary license.
| Brand Name | Manufacturer | Headquartered | Notes |
|---|---|---|---|
| TAFFIC | Hetero Drugs Ltd. | Hyderabad, India | First Indian generic; Dec 2019 launch; world’s largest ARV producer |
| BIC/FTC/TAF (generic) | Cipla Ltd. | Mumbai, India | Licensed; major global ARV supplier; WHO-prequalified facilities |
| BIC/FTC/TAF (generic) | Sun Pharmaceutical | Mumbai, India | Licensed under MPP; major multinational generics company |
| BIC/FTC/TAF (generic) | Mylan / Viatris | Hyderabad, India | Formerly Mylan; now Viatris; longstanding global ARV manufacturer |
| BIC/FTC/TAF (generic) | Strides Pharma | Bengaluru, India | Licensed; strong export focus; regulated-market approved |
| BIC/FTC/TAF (generic) | SeQuent Scientific | Mumbai, India | API and formulation manufacturer; licensed sub-licensee |
Before sourcing any generic Biktarvy from India, verify the manufacturer holds (1) DCGI approval and ideally (2) WHO prequalification. Never purchase from unverified online sources, social media sellers, or unregulated marketplaces. These are life-sustaining medications — source them with the same care you would the brand-name drug.
Is It Legal to Import Biktarvy from India to the USA?
This is the question most American HIV patients ask when they discover the Biktarvy price in India. It demands a careful, legally accurate, and honest answer — not a blanket yes or no.
The Strict Legal Reality
Under U.S. federal law — specifically 21 U.S.C. § 384 — importing a drug not approved by the FDA is generally prohibited. Indian generic Biktarvy (TAFFIC, etc.) is not FDA-approved. Technically, importing it is illegal.
The FDA’s Personal Importation Policy: A Critical Nuance
However, the FDA has maintained a longstanding Personal Importation Policy (PIP) that establishes enforcement discretion. The FDA states it will generally consider not pursuing prosecution when all of the following conditions are met:
The drug is for a serious or life-threatening conditionHIV clearly qualifies as a serious condition requiring continuous treatment.
The product does not represent an unreasonable riskLicensed Indian generics from WHO-prequalified facilities are not considered unreasonably risky.
The patient affirms the drug is for personal use onlyA written personal use affirmation is required. Importation for resale is strictly illegal under all circumstances.
A licensed U.S. physician is overseeing the treatmentThe name and contact of the treating physician must be provided to Customs if requested.
The quantity does not exceed a 90-day (3-month) supplyThis is the most cited threshold. Do not order more than a 3-month supply at one time.
The FDA’s personal importation policy is a statement of prosecutorial discretion — it is not a legal right or guarantee. The FDA retains full legal authority to refuse, detain, or seize any imported drug at any time. Outcomes can vary. Consult a healthcare attorney before making any importation decision. Never import more than a 90-day supply. Never import for resale.
Step-by-Step: Safely Accessing Biktarvy from India
If you have consulted your physician and a legal professional and decided to explore accessing licensed generic Biktarvy from India, here is the most responsible framework for doing so safely.
Consult Your HIV Specialist — Before Anything ElseYour physician must know your medication source regardless of where it comes from. They need to continue monitoring your viral load, CD4 count, and potential drug interactions. Ensure your treatment plan is fully documented.
Obtain a Valid, Current PrescriptionYou need a valid prescription specifying: drug name (bictegravir/emtricitabine/tenofovir alafenamide), dose, quantity, and your physician’s full contact details. This is essential for customs and personal-use documentation.
Use Only Verified International Pharmacy SourcesPharmacyChecker.com independently verifies international online pharmacies’ credentials and regulatory compliance. Source only from pharmacies listed there.
Order No More Than a 90-Day SupplyThe FDA’s personal importation tolerance is explicitly limited to a three-month supply. Ordering more risks seizure and removes any policy protection.
Confirm the Manufacturer Is DCGI-Approved and WHO-PrequalifiedAlways confirm the specific manufacturer and facility before ordering.
Inspect Your Medication Upon ArrivalVerify: intact tamper-evident packaging, clear legible labeling, valid expiration date, tablet appearance consistent with description. Contact your pharmacist or physician immediately if anything appears unusual.
Maintain All Scheduled Monitoring AppointmentsContinue your viral load tests, CD4 count monitoring, and all routine clinical appointments without interruption.
U.S. Patient Assistance Programs — Exhaust These First
Before considering importation, every American HIV patient should exhaust all available domestic assistance options. Many patients qualify for significantly reduced or zero-cost Biktarvy through these programs.
Gilead Advancing Access® Program
Gilead’s own program. Commercially insured patients: often $0–$5/month copay. Uninsured who qualify: may receive medication at no cost.
gileadadvancingaccess.com
Phone: 1-800-226-2056
Ryan White HIV/AIDS Program
Federal program for low-income, uninsured, and underinsured people living with HIV. Covers medications and HIV care across all 50 states.
State AIDS Drug Assistance Programs (ADAPs)
Every U.S. state has an ADAP providing HIV medications at reduced or no cost to eligible residents. Income thresholds vary by state.
GoodRx Savings Coupons
Can reduce out-of-pocket costs at U.S. retail pharmacies. Always compare GoodRx price vs. your insurance copay.
NeedyMeds
Nonprofit database of over 10,000 patient assistance programs. Search by drug name or diagnosis.
Gilead Price Transparency Info
See Biktarvy list price, net price, and assistance program details in one place directly from Gilead.
Frequently Asked Questions
All Sources & External Links
Every factual claim in this article is supported by a primary, government, or well-established medical source. We link only to authoritative references — never to unverified sites.
- 01FDA — Biktarvy Full Prescribing Information (2025)
- 02DHHS — Adult & Adolescent Antiretroviral Guidelines
- 03Gilead Price Info — Official Biktarvy WAC Pricing
- 04Drugs.com — Biktarvy Price Guide
- 05GoodRx — Biktarvy Without Insurance
- 06Pharmacy Times — Biktarvy 5.9% Price Increase January 2025
- 07Healthline — Biktarvy Cost Overview (2026)
- 08PharmacyChecker — Verified International Biktarvy Prices
- 09Everyone.org — Biktarvy Global Access Guide
- 11Gilead Sciences — MPP Voluntary License for Bictegravir (2017)
- 12Medicines Patent Pool — Official Site & License Database
- 13MSF Access Campaign — How Voluntary Licenses Work (Full Brief PDF)
- 14Hetero Drugs — TAFFIC Launch Press Release (Dec 2019)
- 15Wikipedia — Bictegravir (licensing & global approvals)
- 16Wikipedia — Gilead Sciences (voluntary licensing history)
- 17WHO — Prequalified Medicines List
- 18NACO — National AIDS Control Organisation of India
- 19IndiaMart — Indian Generic Biktarvy Trade Reference
- 20FDA — Personal Importation Policy (official)
- 21KFF — FAQs on Prescription Drug Importation
- 22Cornell Law — 21 U.S. Code § 384 (Drug Importation Statute)
- 23Everyone.org — Guide to Importing Medicines into the USA
- 24NABP — .Pharmacy Verification Program
- 25Gilead Advancing Access — Patient Assistance Program
- 26HRSA — Ryan White HIV/AIDS Program
- 27HRSA — State ADAP Directory
- 28ADAP Advocacy Association
- 29GoodRx — Biktarvy Savings
- 30NeedyMeds — Patient Assistance Program Database
- 31KFF — U.S. Drug Prices vs. Other Countries